Helena Fatouros Bergman
Adjunct Lecturer
| Docent
E-mail: helena.fatouros-bergman@ki.se
Telephone: 070-737 51 02
Visiting address: Norra Stationsgatan 69, plan 7, 11364 Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 CPF Fortbildning, 171 77 Stockholm
Part of:
About me
- CURRENT POSITION
18.04.01.- ongoing *Section head of Continuing Professional
Developmen*t, Centre for Psychiatry Research (CPF), Department of Clinical
Neuroscience, Karolinska Institutet & Stockholms Läns Sjukvårdsområde
(SLSO).
21.03.09. *Docent in Psychology* at the Department of Clinical
Neuroscience, Karolinska Institutet.
COURSES AND DEGREES
1993-1998 Psychology Program (MSci) at the Department of Psychology at
Stockholm University, Sweden, (300 credits)
DOCTORAL DEGREE
6 th March 2009: Ph.D. “Emotional interplay and Communication with patients
diagnosed with Schizophrenia”, Department of Psychology at Stockholm
University, Sweden.
POSTDOC APPOINTMENTS
2009-2016 Postdoctoral fellow (50%),
Center for Psychiatry Research (CPF), Department of Clinical Neuroscience,
Karolinska Institutet. Position with focus on cognition and Schizophrenia
situated within Karolinska Schizophrenia Project (KaSP). Post doc mentors
ass. prof. Lena Flyckt and prof. Lars Farde.
Research
- My research has during my whole career been focused on different aspects of
psychosis and Schizophrenia, and more specific *cognitive functions and
Schizophrenia*. After my dissertation in 2009 I got a post doc position with
focus on cognition and schizophrenia at the Centre for Psychiatry Research at
Karolinska Institutet. Post doc mentors were ass. prof. Lena Flyckt and prof.
Lars Farde. This position was in a new project called Karolinska
Schizophrenia Project (KaSP). Several groups working with schizophrenia
research at Karolinska Institutet started to collaborate and the overall aim
was to examine if brain immune activation is associated with the
pathophysiology in schizophrenia. More specific the project enrolls first
episode psychosis patients that were either antipsychotic drug naïve or
sparingly medicated for less than one month. They undergo an ambitious
project of examinations at baseline and at 1, 5 year follow up. I am
responsible for the cognitive database.
Up to today we have enrolled 100 patients and 65 controls at baseline and
approximately half of them have done their 1.5 year follow up. The project is
still ongoing and the plan is to continue collecting data for many years. It
has resulted in numerous publications in high impact journals and highlights
a multidisciplinary and translational strategy aimed at examining the
pathophysiology of schizophrenia involving both clinical and pre-clinical
researchers. I am responsible for the cognitive database and currently
working with analyses of these data. For more information about the KaSP
project
see: https://ki.se/en/research/the-karolinska-schizophrenia-project-kasp?_ga=2.192792680.350689484.1540983977-24002046.1535100567
[1]
Following are some of the most important publications that the KaSP project
has resulted in, and many other publications are in pipeline:
1. Lower levels of the glial cell marker TSPO in drug-naive
first-episode psychosis patients as measured using PET and [11C]PBR28.
Collste K, Plavén-Sigray P, */Fatouros-Bergman H/*, Victorsson P, Schain M,
Forsberg A, Amini N, Aeinehband S - Karolinska Schizophrenia Project (KaSP)
consortium, Erhardt S, Halldin C, Flyckt L, Farde L, Cervenka S. Mol
Psychiatry. 2017 Jun - 22(6):850-856. doi: 10.1038/mp.2016.247. PMID: 28194003
Impact Factor: 11.640 https://www.ncbi.nlm.nih.gov/pubmed/28194003 [2]
2. CSF GABA is reduced in first-episode psychosis and associates to
symptom severity. Orhan F, */Fatouros-Bergman H/*, Goiny M, Malmqvist A,
Piehl F - Karolinska Schizophrenia Project (KaSP) Consortium, Cervenka S,
Collste K, Victorsson P, Sellgren CM, Flyckt L, Erhardt S, Engberg G. Mol
Psychiatry. 2017 Mar 14. doi: 10.1038/mp.2017.25. PMID: 28289277 Impact
Factor: 11.640 https://www.ncbi.nlm.nih.gov/pubmed/28289277 [3]
3. Cerebellar volume and cerebellocerebral structural covariance in
schizophrenia: a multisite mega-analysis of 983 patients and 1349 healthy
controls. Moberget T, Doan NT, Alnæs D, Kaufmann T, Córdova-Palomera A,
Lagerberg TV, Diedrichsen J, Schwarz E, Zink M, Eisenacher S, Kirsch P,
Jönsson EG, / *Fatouros-Bergman H*/, Flyckt L - KaSP, Pergola G, Quarto T,
Bertolino A, Barch D, Meyer-Lindenberg A, Agartz I, Andreassen OA, Westlye
LT. Mol Psychiatry. 2017 May 16. doi: 10.1038/mp.2017.106. PMID:
28507318 Impact Factor: 11.640 https://www.ncbi.nlm.nih.gov/pubmed/28507318
[4]
[1] https://ki.se/en/research/the-karolinska-schizophrenia-project-kasp?_ga=2.192792680.350689484.1540983977-24002046.1535100567
[2] https://www.ncbi.nlm.nih.gov/pubmed/28194003
[3] https://www.ncbi.nlm.nih.gov/pubmed/28289277
[4] https://www.ncbi.nlm.nih.gov/pubmed/28507318
Teaching
- I am currently Section head of Continuing Professional Development at Centre
for Psychiatry Research (CPF), Department of Clinical Neuroscience,
Karolinska Institutet & Stockholms Läns Sjukvårdsområde (SLSO) and
responsible for continuing professional development educations within
psychiatry see
http://psykiatriforskning.se/Utbildning/ [1]
I teach and function as course leader and examiner at the Research School in
Clinical Psychiatry (KI/SLL) at Karolinska
Institutet https://ki.se/doktorand/forskarskola-kisll-inom-klinisk-psykiatri
[2]
I also currently teach at the medical program at
KI https://ki.se/utbildning/2lk13-lakarprogrammet [3]
and at METIS (courses for ST-läkare, resident in
psychiatry) http://www.metiskurser.se/ [4]
My area of teaching has been in my area of expertise that is schizophrenia.
However, I have also focused on several other topics, such ar for example how
to write high quality grant applications and how to construct a research
budget.
[1] http://psykiatriforskning.se/Utbildning/
[2] https://ki.se/doktorand/forskarskola-kisll-inom-klinisk-psykiatri
[3] https://ki.se/utbildning/2lk13-lakarprogrammet
[4] http://www.metiskurser.se/
Articles
-
Article: BRAIN BEHAVIOR AND IMMUNITY. 2024;117:313-319
-
Article: JCPP ADVANCES. 2023;3(4):e12179
-
Article: BRAIN BEHAVIOR AND IMMUNITY. 2023;111:376-385
-
Article: SCHIZOPHRENIA RESEARCH. 2023;257:34-40
-
Article: NATURE COMMUNICATIONS. 2022;13(1):6427
-
Article: HELIYON. 2022;8(9):e10424
-
Article: JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE. 2022;25:44-60
-
Article: TRANSLATIONAL PSYCHIATRY. 2022;12(1):229
-
Article: MOLECULAR PSYCHIATRY. 2022;27(2):1233-1240
-
Article: HUMAN BRAIN MAPPING. 2022;43(1):352-372
-
Article: HUMAN BRAIN MAPPING. 2022;43(1):431-451
-
Article: HUMAN BRAIN MAPPING. 2022;43(1):452-469
-
Article: HUMAN BRAIN MAPPING. 2022;43(1):244-254
-
Article: NPJ SCHIZOPHRENIA. 2021;7(1):46
-
Article: SCIENTIFIC REPORTS. 2021;11(1):7527
-
Article: BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING. 2020;5(12):1095-1103
-
Article: NATURE COMMUNICATIONS. 2020;11(1):4016
-
Article: IBRO REPORTS. 2020;8:136-142
-
Journal article: SCHIZOPHRENIA BULLETIN. 2020;46(Supplement_1):s135-s136
-
Article: NATURE NEUROSCIENCE. 2019;22(10):1617-1623
-
Article: SCHIZOPHRENIA RESEARCH. 2019;210:221-227
-
Article: JAMA PSYCHIATRY. 2019;76(7):739-748
-
Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):12
-
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2018;138(5):432-440
-
Article: BIOLOGICAL PSYCHIATRY. 2018;84(9):644-654
-
Article: MOLECULAR PSYCHIATRY. 2018;23(6):1512-1520
-
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2018;115(22):E5154-E5163
-
Article: MOLECULAR PSYCHIATRY. 2018;23(5):1261-1269
-
Article: MOLECULAR PSYCHIATRY. 2018;23(5):1244-1250
-
Article: PSYCHOLOGICAL MEDICINE. 2018;48(1):82-94
-
Article: SCHIZOPHRENIA BULLETIN. 2017;43(4):914-924
-
Article: MOLECULAR PSYCHIATRY. 2017;22(6):850-856
-
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2017;135(5):439-447
-
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2016;84(5):262-271
-
Article: INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY. 2015;61(7):684-692
-
Article: SYNAPSE. 2015;69(7):365-374
-
Article: SCHIZOPHRENIA RESEARCH. 2014;158(1-3):156-162
-
Article: SCHIZOPHRENIA RESEARCH AND TREATMENT. 2012;2012:867424-6
-
Article: PSYCHOSIS-PSYCHOLOGICAL SOCIAL AND INTEGRATIVE APPROACHES. 2011;3(2):148-150
-
Article: HUMAN STUDIES. 2011;34(1):23-42
-
Article: INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING. 2011;6(1):5412
- Show more
All other publications
-
Letter: BRAIN BEHAVIOR AND IMMUNITY. 2023;114:163-164
-
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2021;41(1_SUPPL):260-261
-
Corrigendum: NATURE NEUROSCIENCE. 2020;23(2):295
-
Conference publication: SCHIZOPHRENIA BULLETIN. 2020;46:S135-S136
-
Letter: SCHIZOPHRENIA RESEARCH. 2019;208:490-492
-
Letter: BIOLOGICAL PSYCHIATRY. 2019;85(7):e35-e39
-
Conference publication: NEUROPSYCHOPHARMACOLOGY. 2019;44(SUPPL 1):169-170
-
Letter: SCHIZOPHRENIA RESEARCH. 2018;199:438-441
-
Letter: SCHIZOPHRENIA RESEARCH. 2018;195:406-408
-
Preprint: 2018;bioRxiv
-
Conference publication: NEUROPSYCHOPHARMACOLOGY. 2017;42:S220-S221
-
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:234
-
Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2016;36:676
-
Review: LAKARTIDNINGEN. 2015;112:DH34
-
Meeting abstract: EUROPEAN PSYCHIATRY. 2015;30:277
-
Meeting abstract: EUROPEAN PSYCHIATRY. 2015;30:270
- Show more
Employments
- Adjunct Lecturer, Department of Clinical Neuroscience, Karolinska Institutet, 2022-2024
Degrees and Education
- Docent, Karolinska Institutet, 2021